Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: Consistent results from a randomized trial and an observational cohort

HIV Medicine

Volumn 2, Issue 1, 2001, Pages 43-51

  Kirk, O ^a   Gerstoft, J ^a   Pedersen, C ^b   Nielsen, H ^c   Obel, N ^d   Katzenstein, Tl ^a   Mathiesen, L ^a   Lundgren, Jd ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adverse drug reactions; Discontinuation; Observational study; Protease inhibitor treatment; Randomized trial

Indexed keywords

INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; NEPHROTOXICITY; NEUROTOXICITY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; RITONAVIR; SAQUINAVIR; TREATMENT FAILURE; TREATMENT REFUSAL; WEIGHT LOSS;

EID: 0035194458     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2001.00045.x     Document Type: Article

References (22)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
2. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease
7. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
8. HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications
9. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
10. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study)
11. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
12. The Danish Protease Inhibitor Study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
13. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
14. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
15. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
16. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: A retrospective cohort study
17. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
18. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
19. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
20. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
21. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
22. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel